Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Current Appointments & Affiliations
Stewart, Hughes and Wendt Distinguished Professor
·
2023 - Present
Neurology, Neuromuscular Disease,
Neurology
Professor of Neurology
·
2018 - Present
Neurology, Neuromuscular Disease,
Neurology
Faculty Network Member of the Duke Institute for Brain Sciences
·
2011 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Associate of the Duke Initiative for Science & Society
·
2017 - Present
Duke Science & Society,
University Initiatives & Academic Support Units
Recent Publications
ALSUntangled #81: Pyridostigmine (mestinon®).
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · May 2026 Pyridostigmine (Mestinon®, Bausch Health, Canada Inc.) increases acetylcholine availability at the neuromuscular junction, enhancing transmission. Preclinical studies suggest that neuromuscular junction dysfunction develops early in ALS, and pyridostigmine ... Full text Link to item CiteALS untangled #83: clenbuterol.
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · March 8, 2026 ALS Untangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review clenbuterol, a β-2 adrenergic agonist, as a potential treatment for amyotrophic lateral sclerosis (ALS). Clenbuterol has ... Full text Link to item CiteALSUntangled #82: N-acetylcysteine.
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · March 4, 2026 N-acetylcysteine is a thiol-containing compound and a precursor of glutathione, with mechanistic plausibility for ALS, including reducing oxidative stress, regulating neuroinflammation, and mitigating mitochondrial dysfunction. Preclinical studies have yie ... Full text Link to item CiteRecent Grants
Healy ALS Platform Study - Regimen I - NUZ-001 TO#14
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2026 - 2030Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATE)
ResearchPrincipal Investigator · Awarded by University of Miami · 2025 - 2030SEA-NOBI-ALS
Clinical TrialPrincipal Investigator · Awarded by WideTrial, Inc. · 2025 - 2028View All Grants
Education
University of Connecticut ·
1995
M.D.
University of Connecticut ·
1995
Ph.D.